The KDIGO (Kidney Disease Improving Global Outcomes) guidelines for glomerulonephritis from 2012 suggest use of prophylactic warfarin in NS patients with high risk of VTE, especially patients with membranous nephropathy, with serum albumin <20–25g/L who also have a low risk of bleeding [16]. This evidence concerns the gene ALB and membranous glomerulonephritis.